Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al

Clin Exp Rheumatol. 2023 Sep;41 Suppl 135(9):8. doi: 10.55563/clinexprheumatol/85mraz. Epub 2021 Sep 7.

Authors

Emine Duran¹, Beste Ekin Sandalcı Yildirim², Ömer Karadağ³

Affiliations

¹ Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey. docemineduran@gmail.com.
² Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey.
³ Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey.

PMID: 34494954
DOI: 10.55563/clinexprheumatol/85mraz

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antirheumatic Agents* / adverse effects
Arthritis, Rheumatoid* / diagnosis
Arthritis, Rheumatoid* / drug therapy
Humans
Rituximab / adverse effects
Treatment Outcome
Tumor Necrosis Factor Inhibitors / therapeutic use

Substances

Rituximab
tocilizumab
Tumor Necrosis Factor Inhibitors
Antibodies, Monoclonal, Humanized
Antirheumatic Agents